Fulcrum Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Fulcrum Therapeutics, Inc. - FULC
Kahn Swick & Foti, LLC (KSF) is investigating the proposed merger of Fulcrum Therapeutics, Inc. (NasdaqGM: FULC) with Slate Medicines, Inc., where Fulcrum shareholders are expected to own 5.0% of the combined company. KSF aims to determine if the merger and its preceding process are fair and adequate for Fulcrum shareholders. Shareholders with concerns about the transaction are encouraged to contact KSF for legal consultation.
Private funds hold 6.65M Fulcrum Therapeutics (FULC) shares under one adviser.
ADAR1 Capital Management, LLC, and its sole manager, Daniel Schneeberger, have reported beneficial ownership of 6,648,027 common shares, representing 8.7% of Fulcrum Therapeutics (FULC). These shares are directly held by private investment funds managed by ADAR1. Both ADAR1 and Schneeberger share voting and dispositive power over these shares, which are based on 76,381,948 shares outstanding as of September 30, 2026.
Two holders report shared ownership of 6.8 million Fulcrum Therapeutics (FULC) shares.
EcoR1 Capital, LLC, and Oleg Nodelman have reported beneficial ownership of 6,803,785 shares (8.9%) of Fulcrum Therapeutics (FULC) each, with shared voting and dispositive power. Additionally, EcoR1 Capital Fund Qualified, L.P. reported ownership of 6,297,538 shares (8.2%) with similar shared powers. These percentages are based on 76,381,948 shares outstanding as of October 28, 2026, and were disclosed in an amended Schedule 13G filing.
A fund manager reports shared voting power over 6.58M Fulcrum Therapeutics (FULC) shares.
Nantahala Capital Management, LLC, along with managing members Wilmot B. Harkey and Daniel Mack, reported beneficial ownership of 6,575,352 shares of Fulcrum Therapeutics (FULC) as of September 30, 2026, representing an 8.62% stake. This disclosure, filed via an amended Schedule 13G/A, indicates that each reporting person has shared voting and shared dispositive power over these shares, which are held in funds and separately managed accounts controlled by Nantahala.
Form 4 Fulcrum Therapeutics For: 13 November By Investing.com
This article from Investing.com announces the filing of Form 4 for Fulcrum Therapeutics, dated November 13. Form 4 is a document filed with the SEC by company insiders to report transactions in their company's stock. The article provides the title and a Reuters copyright, indicating a standard regulatory filing announcement.
Form 4 Fulcrum Therapeutics For: 13 November By Investing.com
This article from Investing.com announces the publication of a Form 4 filing for Fulcrum Therapeutics on November 13. Form 4 filings are regulatory documents detailing changes in beneficial ownership of a company's securities by insiders. The article provides the title and a timestamp, but no further details about the content of the filing.
Form 4 Fulcrum Therapeutics For: 13 November By Investing.com
This article from Investing.com announces the filing of a Form 4 for Fulcrum Therapeutics on November 13. Form 4 filings are typically used to report changes in beneficial ownership of a company's stock by insiders. The article indicates a 2.45% increase for FULC, the stock symbol for Fulcrum Therapeutics.
Fulcrum Therapeutics, Inc. SEC Filing (Nov 5, 2026)
Fulcrum Therapeutics, Inc. filed an S-4 Form, a Notice of Effectiveness, with the SEC, which became effective on November 4, 2026, at 4:15 P.M. The filing indicates a business combination registration. The article also provides a brief overview of FULC's stock rankings, recent news, and other SEC filings.
An expected ~$270M dividend accompanies Fulcrum Therapeutics (FULC)'s planned merger with Slate.
Fulcrum Therapeutics (FULC) is planning to merge with Slate Medicines, Inc. (SLTE) in a reverse merger transaction. Current Fulcrum stockholders are expected to receive a pre-closing cash dividend of approximately $270 million and retain about 5.0% ownership of the combined company, which will be renamed Slate Medicines, Inc. The merger aims to advance Slate's migraine therapies, including SLTE-1009 and SLTE-2100, and is accompanied by a concurrent $245 million investment in Slate.
Fulcrum Therapeutics, Inc. (FULC) Seasonal Returns Chart - Yahoo Finance
The article provides a seasonal returns chart for Fulcrum Therapeutics, Inc. (FULC), displaying the average monthly price return from 2019 to 2026. As of the market open at 10:15:36 a.m. EST, FULC's real-time price on NasdaqGM was 3.7100 USD, with no change.
Fulcrum Therapeutics, Inc. (FULC) Seasonal returns chart
This article from Yahoo Finance presents a seasonal returns chart for Fulcrum Therapeutics, Inc. (FULC). It displays the average monthly price return for the company's stock from 2019 to 2026. The page also includes real-time pricing information and links to other financial data for FULC.
Amendment: SEC Form SCHEDULE 13G/A filed by Fulcrum Therapeutics Inc.
Quantisnow reported an amendment to SEC Form SCHEDULE 13G/A filed by Fulcrum Therapeutics Inc. (FULC). The report includes historical stock performance after previous FULC headlines, noting a median move of 3.7% in either direction. Quantisnow provides real-time alerts on such filings to its members.
Bank of America amends its passive stake report on Fulcrum Therapeutics (FULC).
Bank of America Corporation has filed an amended Schedule 13G/A, disclosing a 1.5% beneficial ownership in Fulcrum Therapeutics, Inc. (FULC). This amounts to 1,114,867 common shares, over which Bank of America holds shared voting and dispositive power. The filing indicates a neutral impact and sentiment regarding the reported position.
BlackRock reports sole voting power over 5.44M shares in its amended Fulcrum Therapeutics (FULC) stake disclosure.
BlackRock Portfolio Management LLC has filed an amended passive investment disclosure (SCHEDULE 13G/A) for Fulcrum Therapeutics, Inc. (FULC), reporting beneficial ownership of 6,155,437 common shares, representing 8.1% of the class. The filing specifies that BlackRock holds sole voting power over 5,436,791 shares and sole dispositive power over all 6,155,437 shares, with no shared voting or dispositive power. This indicates BlackRock's significant, though passive, influence over Fulcrum Therapeutics.
Fulcrum Therapeutics, Inc. Estimates – NASDAQ:FULC
This page provides financial actuals and analyst estimates for Fulcrum Therapeutics, Inc. (NASDAQ: FULC), covering income statements, balance sheets, cash flow, and valuation metrics. Users can compare reported results against average, high, and low estimates and visualize financial trends over time. The platform emphasizes that the information is not investment advice and encourages users to conduct their own research.
Kaplan Fox is Investigating Whether Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Made Misleading Statements to Investors
Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. (NASDAQ: FULC) following the discontinuation of its pociredir program for sickle cell disease. This decision came after the FDA expressed heightened concerns about the drug's benefit-risk profile due to malignancy risks associated with PRC2 inhibitors, leading to a significant drop in Fulcrum Therapeutics' stock price. The law firm is seeking investors who suffered losses to join their investigation.
Kaplan Fox is Investigating Whether Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Made Misleading Statements to Investors
Kaplan Fox & Kilsheimer LLP is investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) for potential securities violations after the company discontinued its pociredir program due to FDA concerns about malignancy risk. This announcement led to a 51.09% drop in Fulcrum Therapeutics' stock price. The law firm is seeking investors who suffered losses or have information to assist in the investigation.
Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) and Its Officers for Potential Securities Law Violations
Kaplan Fox & Kilsheimer LLP is investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) for potential securities law violations after the company announced the discontinuation of its pociredir program for sickle cell disease. The decision followed heightened FDA concerns regarding the drug's benefit-risk profile due to malignancy risks associated with its mechanism of action, leading to a significant drop in Fulcrum Therapeutics' stock price. The law firm is seeking investors who suffered losses to provide information for their investigation.
Kaplan Fox Announces an Investigation of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) on Behalf of Long-Term Investors
Kaplan Fox & Kilsheimer LLP has announced an investigation into potential securities violations by Fulcrum Therapeutics, Inc. (NASDAQ: FULC) following the discontinuation of its pociredir program for sickle cell disease. The decision came after the FDA raised concerns about the drug's benefit-risk profile due to observed secondary hematologic malignancies, leading to a 51.09% drop in stock price. The firm is seeking investors who suffered losses to assist with the investigation.
Kaplan Fox Reminds Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Investors of an Ongoing Securities Law Investigation
Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. (NASDAQ: FULC) after the company announced the discontinuation of its pociredir program for sickle cell disease. This decision followed heightened FDA concerns regarding the drug's benefit-risk profile due to an unexpectedly high rate of secondary hematologic malignancies observed with another PRC2 inhibitor. Following this news, Fulcrum Therapeutics' stock price declined by over 51%.
Kaplan Fox Notifies Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Investors of an Investigation Into Possible Securities Law Violations
Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations against Fulcrum Therapeutics, Inc. following a significant stock decline. The investigation stems from Fulcrum's announcement on June 1, 2026, to discontinue its pociredir program for sickle cell disease after the FDA raised concerns about the drug's benefit-risk profile due to potential malignancy risks associated with PRC2 inhibitors. This news led to a 51.09% drop in Fulcrum's stock price.
Fulcrum Therapeutics (FULC) Loses 51% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Fulcrum Therapeutics (FULC) has experienced a significant 51% stock decline over the past four weeks, placing it in oversold territory. Despite this, a potential trend reversal is indicated by its Relative Strength Index (RSI) of 21.62 and a 30% increase in consensus EPS estimates from Wall Street analysts over the last 30 days. The stock currently holds a Zacks Rank #2 (Buy), suggesting a strong possibility for a near-term turnaround.
Fulcrum Therapeutics Number of Employees 2026 | Employee Count & Headcount Data
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) has approximately 55 employees worldwide as of March 2026, marking a 4.7% year-over-year increase but a 31.4% decline since 2023. The company is actively hiring with 5 job postings in 2026 and its workforce is primarily concentrated in North America. The average salary is $215,000, and employee sentiment is neutral but improving.
FULC Stock Alert: Halper Sadeh LLC is Investigating Whether Fulcrum Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the merger between Fulcrum Therapeutics, Inc. (NASDAQ: FULC) and Slate Medicines, Inc. The investigation focuses on whether Fulcrum shareholders are receiving a fair price, whether the sales process was free of conflicts of interest, and if all material information was disclosed. Upon closing, Fulcrum shareholders are expected to own 5.0% of the combined company.
Kaplan Fox Launches Investigation Into Fulcrum Therapeutics Following 51% Stock Plunge After Pociredir Program Halt
Kaplan Fox & Kilsheimer LLP has initiated an investigation into Fulcrum Therapeutics, Inc. (NASDAQ:FULC) for potential securities law violations. This comes after Fulcrum announced on June 1, 2026, that it would discontinue its pociredir program for sickle cell disease due to significant FDA concerns regarding the drug's benefit-risk profile, leading to a 51.09% stock plunge. The FDA's decision was influenced by similar malignancy risks associated with another PRC2 inhibitor, Tazverik, which was globally withdrawn.
Kaplan Fox Investigates Fulcrum Therapeutics After Pociredir Discontinuation Triggers 51% Stock Collapse
Kaplan Fox & Kilsheimer LLP has launched an investigation into Fulcrum Therapeutics (NASDAQ: FULC) for potential securities law violations. This follows Fulcrum's decision on June 1, 2026, to discontinue its pociredir program for sickle cell disease due to FDA concerns over its benefit-risk profile, which led to a 51.09% stock drop. The FDA's concerns arose from observed secondary hematologic malignancies with another PRC2 inhibitor, Tazverik®, suggesting similar risks for pociredir and leaving no clear regulatory path.
Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) for Possible Securities Law Violations
Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. (NASDAQ: FULC) after the company announced the discontinuation of its pociredir program for sickle cell disease. This decision followed FDA concerns regarding the drug's benefit-risk profile, particularly an unexpectedly high rate of secondary hematologic malignancies observed with a similar drug. The news led to a significant 51.09% decline in Fulcrum Therapeutics' stock price.
Kaplan Fox Launches Securities Investigation Into Fulcrum Therapeutics After 51% Stock Collapse
Law firm Kaplan Fox & Kilsheimer LLP has initiated a securities investigation into Fulcrum Therapeutics, Inc. (NASDAQ: FULC) following a 51.09% stock drop. This probe comes after Fulcrum announced the discontinuation of its sickle cell disease program for pociredir due to FDA concerns over malignancy risks associated with PRC2 inhibitors. Investors who experienced losses are encouraged to contact the firm regarding potential securities violations.
Former Fulcrum Therapeutics (FULC) officer moves to sell about $54K in stock
A former officer of Fulcrum Therapeutics (FULC), Greg Tourangeau, has filed a Rule 144 notice indicating a planned sale of 14,062 shares of company common stock, valued at approximately $54,419.94 as of September 2, 2026. These shares originated from various equity awards and programs between 2018 and 2025. The filing shows Merrill Lynch, Pierce, Fenner & Smith Inc. as the broker for the potential sale.
Kaplan Fox is Investigating Possible Securities Law Violations Against Fulcrum Therapeutics, Inc. (NASDAQ: FULC)
Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations against Fulcrum Therapeutics, Inc. (NASDAQ: FULC) after the company announced the discontinuation of its pociredir program for sickle cell disease. This decision followed FDA concerns about the drug's safety profile, leading to a significant 51.09% drop in Fulcrum Therapeutics' stock price. The firm is seeking investors who suffered losses or have information relevant to the investigation.
Kaplan Fox Announces an Investigation of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) on Behalf of Investors
Kaplan Fox & Kilsheimer LLP has initiated an investigation into potential securities violations by Fulcrum Therapeutics, Inc. (NASDAQ: FULC) following a significant drop in its stock price. This investigation stems from Fulcrum's announcement to discontinue its pociredir program for sickle cell disease due to FDA concerns regarding the malignancy risk associated with its PRC2 inhibitor. Investors who suffered losses are encouraged to contact Kaplan Fox.
Fulcrum (FULC) is Allocating 95% of the Combined Company to Slate and PIPE Investors. Is the $270M Dividend Enough?
Fulcrum Therapeutics (FULC) is undergoing an all-stock merger with Slate Medicines, transforming into a migraine-focused biotechnology company. The deal involves Slate holders owning 55.9%, PIPE investors 39.1%, and legacy Fulcrum holders 5% of the combined entity, with Fulcrum distributing an estimated $270 million cash dividend ($3.54/share). This transaction effectively offers Fulcrum shareholders a cash payout plus a small stake in Slate's migraine pipeline, which currently lacks human efficacy data.
Fulcrum Therapeutics stock plunges 51% after halting sickle cell drug due to FDA safety concerns
Fulcrum Therapeutics' stock plummeted 51% after the company discontinued its sickle cell disease drug, pociredir, due to FDA safety concerns about a high rate of secondary blood cancers. This decision eliminated any viable regulatory path for the drug's development. Kaplan Fox & Kilsheimer LLP is now investigating potential securities violations, highlighting the significant regulatory risks in drug development for rare diseases.
Slate uses Fulcrum to join Nasdaq with $245M for migraine trials
Slate Medicines is set to list on Nasdaq through a reverse merger with Fulcrum Therapeutics, securing $245 million for migraine trials. The company's lead candidate, SLTE-1009, a monoclonal antibody targeting PACAP and VIP, is expected to have topline safety and pharmacokinetic data in mid-2027, with a phase 2 study planned for the second half of next year. This funding is projected to provide a runway into 2029, also supporting the development of a second candidate, SLTE-2100.
Fulcrum Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Fulcrum Therapeutics, Inc. - FULC
Kahn Swick & Foti, LLC (KSF) is investigating the proposed merger of Fulcrum Therapeutics, Inc. (NasdaqGM: FULC) and Slate Medicines, Inc. The law firm is examining whether the merger and its process are fair to Fulcrum shareholders, who are expected to own 5.0% of the combined company. Shareholders are encouraged to contact KSF for legal consultation regarding their rights.
Slate Medicines to Merge With Fulcrum Therapeutics
Cooley advised Slate Medicines on its definitive agreement to combine with Fulcrum Therapeutics in an all-stock reverse merger. The combined company will operate as Slate Medicines, Inc. and is expected to trade on Nasdaq under "SLTE." In conjunction with the merger, Cooley also advised Slate on an oversubscribed concurrent private placement financing of $245 million.
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Contact the Firm Regarding an Investigation Into Possible Securities Law Violations
Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations against Fulcrum Therapeutics, Inc. (NASDAQ: FULC) following a significant drop in its stock price. The decline occurred after the company announced the discontinuation of its pociredir program for sickle cell disease due to FDA concerns about malignancy risks associated with PRC2 inhibitors. Investors who suffered losses are encouraged to contact Kaplan Fox for more information regarding this investigation.
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Contact the Firm Regarding an Investigation Into Possible Securities Law Violations
Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations by Fulcrum Therapeutics, Inc. (NASDAQ: FULC) after the company discontinued its pociredir program due to FDA concerns about an unexpectedly high rate of secondary hematologic malignancies. This announcement led to a significant 51.09% drop in Fulcrum Therapeutics' stock price. The firm is encouraging investors who have suffered losses or have relevant information to contact them regarding this investigation.
Shareholder Alert: Ademi LLP investigates whether Fulcrum Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders
Ademi LLP is investigating Fulcrum Therapeutics (Nasdaq: FULC) regarding potential breaches of fiduciary duty related to its transaction with Slate Medicines. The investigation focuses on whether Fulcrum's public shareholders are receiving a fair price, given that they are expected to own only 5.0% of the combined company while Slate shareholders will own 95.0%. The firm is also scrutinizing the board's conduct and the transaction's terms, including a significant penalty for accepting competing bids.
Latham Advises Frazier Life Sciences on Private Placement Financing With Fulcrum Slate Merger
Latham & Watkins LLP advised Frazier Life Sciences on an oversubscribed US$245 million private placement financing. This financing supports the merger between Fulcrum Therapeutics, Inc. (Nasdaq: FULC) and Slate Medicines, Inc., an all-stock transaction. The combined company will focus on advancing Slate’s pipeline, including SLTE-1009 for migraine treatment, and will trade on Nasdaq under the symbol SLTE.
Form 8K Fulcrum Therapeutics Inc For: 17 August By Investing.com
This article reports that Fulcrum Therapeutics Inc. filed a Form 8K on August 17. The filing is brief and does not provide further details within the article text. The content also includes market data and related news headlines.
Shareholder Alert: Ademi LLP investigates whether Fulcrum Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders
Ademi LLP is investigating Fulcrum Therapeutics, Inc. (Nasdaq: FULC) for potential breaches of fiduciary duty related to its transaction with Slate Medicines. The investigation focuses on whether public shareholders are receiving a fair price, given that pre-merger Fulcrum stockholders will own only 5.0% of the combined company and insiders are set to receive substantial benefits. Ademi LLP is also examining whether the transaction agreement unfairly limits competing bids for Fulcrum.
Fulcrum Therapeutics (NASDAQ: FULC) backs $245M migraine venture with Slate
Fulcrum Therapeutics and Slate Medicines announced an all-stock merger, forming a new entity named Slate Medicines, Inc. that will trade on Nasdaq as "SLTE." The combined company will focus on Slate's pipeline, particularly SLTE-1009 for migraine prevention, supported by a $245 million private placement from investors led by Frazier Life Sciences. This funding is expected to support operations into 2029 as SLTE-1009 advances through clinical trials.
Shareholder Alert: Ademi LLP investigates whether Fulcrum Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders
Ademi LLP is investigating Fulcrum Therapeutics, Inc. (Nasdaq: FULC) regarding its recently announced transaction with Slate Medicines, suspecting possible breaches of fiduciary duty. Under the merger agreement, pre-Merger Fulcrum stockholders are expected to own only 5.0% of the combined company, with Slate stockholders owning 95.0%. The investigation focuses on whether Fulcrum's board is fulfilling its fiduciary duties to shareholders given the low ownership percentage for existing shareholders and a significant penalty if Fulcrum accepts a competing bid.
Fulcrum Therapeutics shuts down, reverse-merges with N.C. biotech Slate
Fulcrum Therapeutics, which previously cut 85% of its workforce after discontinuing its sickle cell disease program, is undergoing a reverse merger with North Carolina-based Slate Medicines. The merger is anticipated to finalize in the fourth quarter of the year. Fulcrum is currently located at 26 Landsdowne St., occupying significant office and laboratory space.
Slate, Fulcrum to combine in reverse merger
Slate Medicines will acquire Fulcrum Therapeutics in a reverse merger, two months after Fulcrum halted its sickle cell drug development due to regulatory concerns. The combined company, operating under Slate's name and led by Slate CEO Gregory Oakes, will focus on developing migraine therapeutics. Fulcrum shareholders will receive a cash dividend and own 5% of the new entity, with Slate investors holding the remaining 95%.
Fulcrum Therapeutics stock rises on Slate Medicines merger deal
Fulcrum Therapeutics Inc (NASDAQ:FULC) shares rose after announcing a definitive agreement to merge with Slate Medicines Inc in an all-stock transaction. The combined company, to be named Slate Medicines, will focus on advancing migraine therapeutics and secured an oversubscribed private placement of $245 million to fund operations into 2029. The merger is expected to close in Q4 2026, with Fulcrum stockholders owning 5.0% of the combined entity.
Kaplan Fox Alerts Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Possible Securities Law Violations
Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations against Fulcrum Therapeutics, Inc. (NASDAQ: FULC) after the company announced the discontinuation of its pociredir program for sickle cell disease. This decision followed heightened FDA concerns regarding the drug's benefit-risk profile due to malignancy risks associated with PRC2 inhibitors, leading to a significant 51.09% stock price decline on June 2, 2026. Investors who suffered losses are encouraged to contact Kaplan Fox for more information on the investigation.
Fulcrum Therapeutics Merges With Slate in $245M Migraine Biotech Deal
Fulcrum Therapeutics is merging with Slate Medicines, a privately held migraine-focused biotech company, in an all-stock transaction valued at $245 million, expected to close in Q4 2026. The combined entity will be renamed Slate Medicines and trade under the Nasdaq ticker SLTE. This deal includes a private placement, a special cash dividend for pre-merger Fulcrum shareholders, and is projected to provide the new company with operational funding until 2029, focusing on Slate's lead migraine drug candidates, SLTE-1009 and SLTE-2100.
Fulcrum to merge with Slate in all-stock deal after drug setback
Fulcrum Therapeutics announced an all-stock merger with privately held Slate Medicines following the discontinuation of its lead drug candidate. The combined company will operate as Slate Medicines, trading under the ticker "SLTE" on Nasdaq, and gains access to Slate's experimental migraine drug, SLTE-1009. The deal includes a $245 million private placement, expected to fund operations into 2029 and advance its pipeline.